Tamoxifen use was associated with a reduced risk of contralateral breast cancer risk in BRCA1 carriers in the univariate analysis (RR 0.55; 95% CI 0.31–0.94; P=0.03); but not after adjustment for age of diagnosis and the other treatments (Table 5). The gene discussed is BRCA1; the disease is breast carcinoma.